Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Accumulated Expenses (2023 - 2025)

Beta Bionics' Accumulated Expenses history spans 3 years, with the latest figure at $22.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 41.72% year-over-year to $22.4 million; the TTM value through Dec 2025 reached $22.4 million, up 41.72%, while the annual FY2025 figure was $22.4 million, 41.72% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $22.4 million at Beta Bionics, up from $17.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $22.4 million in Q4 2025 and bottomed at $8.1 million in Q4 2023.
  • The 3-year median for Accumulated Expenses is $14.6 million (2024), against an average of $14.7 million.
  • The largest annual shift saw Accumulated Expenses soared 94.73% in 2024 before it soared 41.72% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $8.1 million in 2023, then skyrocketed by 94.73% to $15.8 million in 2024, then soared by 41.72% to $22.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Accumulated Expenses are $22.4 million (Q4 2025), $17.6 million (Q3 2025), and $13.4 million (Q2 2025).